Sign In to Follow Application
View All Documents & Correspondence

Novel Compound Acting As A Cannabinoid Receptor 1 Inhibitor

Abstract: Disclosed are a novel compound acting as a cannabinoid receptor 1 inhibitor a prodrug thereof a pharmaceutically acceptable salt thereof and a hydrate thereof or a solvate thereof. The novel compound or the like is useful for preventing or treating diseases mediated by cannabinoid receptor 1.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
22 February 2013
Publication Number
36/2016
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
knk@kankrishme.com
Parent Application
Patent Number
Legal Status
Grant Date
2019-08-02
Renewal Date

Applicants

AMOREPACIFIC CORPORATION
181 2 ga Hangang ro Yongsan gu Seoul 140 777

Inventors

1. SHIN Song Seok
#102 2003 SK Apt. 700 Seocheon dong Giheung gu Yongin si Gyeonggi do 446 959
2. HONG Yong Deog
#12 102 Kkachi Heights Villa 711 15 Geumjeong dong Gunpo si Gyeonggi do 435 827
3. BYOUN Kyoung Hee
#503 2103 Hanbora Maeul Humansia 5 Danji Apt. Bora dong Giheung gu Yongin si Gyeonggi do 446 752
4. PARK Mi Young
#1002 401 Jugong Apt. Jungang dong Gwacheon si Gyeonggi do 427 741
5. CHOI Jin Kyu
#126 1601 Hyundai Hillstate Maetan dong Yeongtong gu Suwon si Gyeonggi do 443 370
6. PARK Yang Hui
#237 Sungwoo Starwoos Officetel Gumi dong Bundang gu Seongnam si Gyeonggi do 463 860
7. BAE Il Hong
#504 402 Hanbora Maeul Humansia 5 Danji Apt. Bora dong Giheung gu Yongin si Gyeonggi do 446 752
8. JOO Yung Hyup
#2108 1901 Baekhyeon Maeul Dongil Hivill Apt. Jung dong Giheung gu Yongin si Gyeonggi do 446 753
9. LIM Kyung Min
#320 1205 Sibeom Daeun Maeul Posco The Sharp Apt. Bansong dong Hwaseong si Gyeonggi do 445 724
10. PARK Young Ho
#3 1201 Daelim Apt. Sadang 3 dong Dongjak gu Seoul 156 775

Specification

【CLAIMS】
【Claim 1】
A compound of Chemical Formula 1, a prodrug thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof:

wherein
R1 is selected from a group consisting of hydrogen, C1-C5 alkyl, haloalkyl, C1-C5 cycloalkyl and C1-C5 alkoxyalkyl;
each of R2, R3, R4, R5 and R6 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, C1-C5 alkyl, hydroxy C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkoxy alkyl, halo C1-C3 alkyl, halo C1-C5 alkoxy, haloalkoxy C2-C5 alkenyl, C2-C5 alkenyl, alkynyl, carboxyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylaminocarbonyl, C1-C5 alkylsulfanyl, C1-C5 alkylsulfonyl, C1-C5 alkoxysulfonyl, C1-C5 alkylsulfamoyl, aryl, aryl C1-C3 alkyl, aryl C1-C5 alkoxy, aminosulfonyl, C1-C5 alkylamino, C1-C5 alkylaminosulfonyl, C1-C5 alkylsulfonylamino, C1-C5 alkylthio, C3-C7


selected from R2 through R6 form a 5- to 7-membered ring fused with an aryl group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O or S atoms;
each of R7, R8, R9, R10 and R11 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo C1-C3 alkyl, haloalkoxy C1-C5 alkenyl, C2-C5 alkenyl and alkynyl; and
each of R12 and R13 is independently selected from a group consisting of hydrogen, C1-C5 alkyl, hydroxy C2-C5 alkyl, C3-C7 cycloalkyl and halo C1-C5 alkyl, or R12 and R13 form a 5- to 7-membered ring together with the nitrogen atom which they are bound and the ring contains 0-2 N, O or S atoms or at least one substituent selected from a group consisting of hydrogen, hydroxy, hydroxy C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkoxy alkyl, halo C1-C5 alkyl, halo C1-C5 alkoxy and carboxyl.
【Claim 2】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 1, wherein the compound is represented by Chemical Formula 2:
[Chemical Formula 2]


wherein
R1 is selected from a group consisting of hydrogen, C1-C5 alkyl, haloalkyl, C1-C5 cycloalkyl and C1-C5 alkoxyalkyl;
each of R2, R3, R4, R5 and R6 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, C1-C5 alkyl, hydroxy C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkoxy alkyl, halo C1-C3 alkyl, halo C1-C5 alkoxy, haloalkoxy C2-C5 alkenyl, C2-C5 alkenyl, alkynyl, carboxyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylaminocarbonyl, C1-C5 alkylsulfanyl, C1-C5 alkylsulfonyl, C1-C5 alkoxysulfonyl, C1-C5 alkylsulfamoyl, aryl, aryl C1-C3 alkyl, aryl C1-C5 alkoxy, aminosulfonyl, C1-C5 alkylamino, C1-C5 alkylaminosulfonyl, C1-C5 alkylsulfonylamino, C1-C5 alkylthio, C3-C7
cycloalkylsulfonylaminophenyl, , and ^, or two selected
from R2 through R6 form a 5- to 7-membered ring fused with an aryl group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O or S atoms;
each of R7, R8, R9, R10 and R11 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, C1-C5 alkyl, C1-C5

alkoxy, halo C1-C3 alkyl, haloalkoxy C2-C5 alkenyl, C2-C5 alkenyl and alkynyl;
R14 is selected from a group consisting of hydrogen, hydroxy, hydroxy C1-C5 alkyl, C1-C5 alkoxy, C1-C5 alkoxy alkyl, halo C1-C5 alkyl, halo C1-C5 alkoxy and carboxyl; and
n is an integer selected from 1 to 3.
【Claim 3】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 1, wherein the compound is represented by Chemical Formula 3:
[Chemical Formula 3]

wherein
R1 is selected from a group consisting of methyl, ethyl, propyl, butyl, isobutyl, difluoromethyl, trifluoromethyl, cyclopropyl, ethoxymethyl, methoxymethyl and ethoxyethyl;
each of R3, R4 and R5 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, isopropyl,

butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, hydroxymethyl,
hydroxyethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl,
acetylenyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, acetyl, methylsulfanyl,
ethylsulfanyl, methylsulfonyl, methylsulfonylamino, cyclopropylaminosulfonyl,
methylaminosulfonyl, ethylaminosulfonyl, dimethylaminocarbonyl,
diethylaminocarbonyl, methylcarbonylamino, methylsulfamoyl, phenylmethyl, phenylethyl, phenylmethoxy, phenylacetyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, dimethylamino, diethylamino, cyclopropylamino and methylthio, or two selected from R3 through R5 form a 5- to 7-membered ring fused with an aryl group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O or S atoms; and
each of R8, R9 and R10 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl and acetylenyl.
【Claim 4】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 3, wherein:
R1 is selected from a group consisting of methyl, ethyl, propyl, butyl, isobutyl, trifluoromethyl, cyclopropyl, ethoxymethyl, methoxymethyl and ethoxyethyl;
each of R3, R4 and R5 is independently selected from a group consisting of

hydrogen, fluoro, chloro, nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, methylenedioxy, isopropoxy, hydroxymethyl, hydroxyethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl, acetylenyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, acetyl, methylsulfonyl, methylsulfamoyl, phenylmethyl, phenylethyl and methylthio, or two selected from R3 through R5 form a 5- to 7-membered ring fused with an aryl group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O or S atoms; and
each of R8, R9 and R10 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, hydroxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl and acetylenyl.
【Claim 5】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 1, wherein the compound is selected from a group consisting of:
{1-[7-(3-chloro-4-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl ]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-chloro-4-fluorophenyl)-3-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyr imidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(3-fluoro-4-methylphenyl)-7-(3-methoxyphenyl)-2-methyl-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[3-(2,4-difluorophenyl)-7-(3-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrim idin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(3-fluoro-4-methylphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(2,4-difluorophenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-chloro-4-fluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3,4-difluorophenyl-3-(3-fluoro-4-methyl-phenyl)-2-methyl-pyrazolo[1,5-a ]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-ethylphenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidi n-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(3-ethylphenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3,5-difluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrim idin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(3,4-difluorophenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-fluorophenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(3,4-difluorophenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo-1,3]dioxol-5-yl-7-(3,5-difluorophenyl)-2-methyl-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[2-ethoxymethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3,5-difluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrim idin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-methoxyphenyl)-2-trifluoromethyl-7-(3-trifluoromethylphenyl)-pyrazol o[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-3-(4-methoxyphenyl)-7-(3-methoxyphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-(4-fluorophenyl)-3-(4-methoxyphenyl)-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-difluoromethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethylphenyl)-pyrazolo [1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-2-ethoxymethyl-7-(3-fluorophenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethyl-7-(4-fluorophenyl)-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin -2-yl}-methanol,
{1-[7-(3-chlorophenyl)-2-ethyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidi n-2-yl}-methanol,
{1-[2-ethyl-7-(3-fluorophenyl)-3-p-tolylpyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-2-ethoxymethyl-7-(3-trifluoromethylphenyl)-pyrazo lo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(3-chlorophenyl)-2-ethoxymethyl-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[2-ethoxymethyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimi
din-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-(3-fluorophenyl)-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimi din-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-m-tolyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-(3-fluorophenyl)-3-(4-methoxyphenyl)-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-(4-fluorophenyl)-3-(4-methoxyphenyl)-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-methoxymethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethylphenyl)-pyrazol o[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-butyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-ethoxymethyl-7-(3-methoxyphenyl)-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-2-ethoxymethyl-7-(3-trifluoromethylphenyl)-pyrazolo[1, 5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-2-ethoxymethyl-7-(4-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-2-ethoxymethyl-7-(3-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[3-(4-chlorophenyl)-2-ethoxymethyl-7-(3-trifluoromethylphenyl)-pyrazolo[1, 5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
2-{[3-(4-chlorophenyl)-2-methoxymethyl-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(4-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyr imidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(3-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyr imidin-5-yl]-pyrrolidin-2-yl}-methanol,
2-{[2-methoxymethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethyl-phenyl)-pyraz olo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-fluorophenyl)-2-methoxymethyl-3-(4-methoxyphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(3-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(4-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-2-methoxymethyl-7-(3-trifluoromethyl-phenyl)-pyra zolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-3-(5-(2-hydroxymethyl)pyrrolidin-1-yl)-2-(methoxymethyl)-3-(4-methoxyph enyl)-pyrazolo[1,5-a]pyrimidin-7-yl)benzonitrile,
(S)-[{1-(2-methoxymethyl)-3-(methoxyphenyl)-7-(m-tolyl)-pyrazolo[1,5-a]-pyri din-5-yl}-pyrrolidin-2-yl]-methanol,
(S)-{[1-(2-methoxymethyl)-7-(3-methoxyphenyl)-3-(4-methoxyphenyl)-pyrazol o[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[3-(4-chlorophenyl)-7-(2,4-difluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidi
n-5-yl]-pyrrolidin-2-yl}-methanol,
[1 -(3-benzo[1,3]dioxol-5-yl-2-methyl-7-phenyl-pyrazolo[1,5-a]pyrimidin-5-yl)-p yrrolidin-2-yl]-methanol,
{1-[3-(4-ethoxyphenyl)-2-methyl-7-phenyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrol idin-2-yl}-methanol,
{1-[3-(4-methoxyphenyl)-2-methyl-7-phenyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
(S)-(1-(7-(3,4-difluorophenyl)-3-(4-ethoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyri midin-5-yl)-pyrrolidin-2-yl)-methanol,
{1-[2-methyl-3-(4-methylsulfanylphenyl)-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3,4-difluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrim idin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3,4-difluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
{1-[7-(3,4-difluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
{1-[7-(3,4-difluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(3,4-difluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidi n-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolid in-2-yl}-methanol,

[1-(2-methyl-7-phenyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl]-methanol,
[1-[3-(4-difluoromethylphenyl)-7-(3-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-difluoromethylphenyl)-7-(3-methoxyphenyl)-2-methyl-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-difluoromethylphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1 ,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-difluoromethylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-difluoromethylphenyl)-2-methyl-7-m-tolyl-pyrazolo[1,5-a]pyrimidin-5-y l]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin -5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-methoxyphenyl)-2-methyl-3-(4-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-ethylphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-ethylphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-methyl-3-(4-trifluoromethylphenyl)-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-chlorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrroli din-2-yl}-methanol,

[1-(2-methyl-3,7-di-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl)-pyrrolidin-2-yl]-metha nol,
{1-[7-(3-chlorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrroli din-2-yl}-methanol,
{1-[7-(3-chlorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrroli din-2-yl}-methanol
[1-(2-methyl-7-m-tolyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl)-pyrrolidin-2-yl]-methanol,
{1-[7-(3-methoxyphenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
{1-[7-(4-methoxyphenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrr olidin-2-yl}-methanol,
{1-[7-(2-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolid in-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(3-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimid in-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-fluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin -5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-ethoxyphenyl)-7-(3-fluoromethylphenyl)-2-methyl-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[2-methyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl ]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-methoxyphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,

{1-[7-(3-chlorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin -5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(3-chlorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimi din-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(4-vinylphenyl)-pyrazolo[1,5-a]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-ethoxyphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-fluoro-3-methylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(3-fluoro-4-methylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]py rimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-ethoxyphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5 -yl]-pyrrolidin-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolid in-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(4-propoxyphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-biphenyl-4-yl-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-(2,4-difluorophenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidi n-5-yl]-pyrrolidin-2-yl}methanol,

{1-[3-(4-ethylsulfanylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrim idin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-(4-butoxyphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5 -yl]-pyrrolidin-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(4-methylsulfanylphenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-(4-benzoyloxyphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimi din-5-yl]-pyrrolidin-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(3-trifluoromethoxyphenyl)-pyrazolo[1,5-a]p yrimidin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(4-trifluoromethoxyphenyl)-pyrazolo[1,5-a]p yrimidin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-(4-ethylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-y l]-pyrrolidin-2-yl}methanol,
{1-[7-(4-fluorophenyl)-2-methyl-3-(4-trifluoromethylphenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}methanol,
1-{4-[7-(4-fluorophenyl)-5-(2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-pyrazolo [1,5-a]pyrimidin-3-yl]phenyl}-ethanol,
{1-[3-(4-tert-butylphenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin -5-yl]pyrrolidin-2-yl}-methanol,
[1-(2-methyl-7-phenyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(3-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolid in-2-yl}-methanol,

{1-[3-(4-chlorophenyl)-2-methyl-7-m-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrroli din-2-yl}-methanol,
{1-[3-benzo[1,3]dioxol-5-yl-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimid in-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[7-(4-fluorophenyl)-3-(4-methoxyphenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin -5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(4-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}methanol,
{1-[3-(4-chlorophenyl)-2-cyclopropyl-7-(3-fluorophenyl)-pyrazolo[1,5-a]pyridin -5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyr idin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(3-fluorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(4-chlorophenyl)-7-(3-chlorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5 -yl]-pyrrolidin-2-yl}-methanol,
{1-[3,7-bis-(4-chlorophenyl)-2-methyl-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(2,4-dichlorophenyl)-2-cyclopropyl-7-(2-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
{1-[3-(2,4-dichlorophenyl)-2-cyclopropyl-7-(4-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[3-(4-chlorophenyl)-2-methyl-7-phenyl-pyrazolo[1,5-a]pyrimidin-5-yl]-py rrolidin-2-yl}methanol,

(S)-{1-[7-(2-fluorophenyl)-2-(methoxymethyl)-3-(4-methoxyphenyl)-pyrazolo[1 ,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[2-ethoxymethyl-3-(4-methoxyphenyl)-7-(3-tolyl)-pyrazolo[1,5-a]pyrimid in-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[7-(3-chlorophenyl)-2-(methoxymethyl)-3-(4-methoxyphenyl)-pyrazolo[ 1,5-a]pyridin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[7-(4-chlorophenyl)-2-(methoxymethyl)-3-(4-methoxyphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[3-(4-chlorophenyl)-2-(methoxymethyl)-7-(3-fluorophenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[3-(4-chlorophenyl)-2-(methoxymethyl)-7-(3-methylphenyl)-pyrazolo[1, 5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[2-butyl-7-(3-tolyl)-3-(4-tolyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[2-butyl-3-(p-tolyl)-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol,
(S)-{1-[2-propyl-3-(p-tolyl)-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyridin-5 -yl]-pyrrolidin-2-yl}-methanol and
(S)-{1-[2-propyl-7-(m-tolyl)-3-(p-tolyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-pyrrolidin-2-yl}-methanol.
【Claim 6】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically

acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 1, wherein the compound is represented by Chemical Formula 4: [Chemical Formula 4]
R6~0 R
WN N^R15
Rs nr Rio
R9
wherein
R1 is selected from a group consisting of methyl, ethyl, propyl, butyl, isobutyl, difluoromethyl, trifluoromethyl, cyclopropyl, ethoxymethyl, methoxymethyl and ethoxyethyl;
each of R3, R4 and R5 is independently selected from a group consisting of
hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, isopropyl,
butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, hydroxymethyl,
hydroxyethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl, vinyl,
acetylenyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, acetyl, methylsulfanyl,
ethylsulfanyl, methylsulfonyl, methylsulfonylamino, cyclopropylaminosulfonyl,
methylaminosulfonyl, ethylaminosulfonyl, dimethylaminocarbonyl,
diethylaminocarbonyl, methylcarbonylamino, methylsulfamoyl, phenylmethyl, phenylethyl, phenylmethoxy, phenylacetyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, dimethylamino, diethylamino, cyclopropylamino and methylthio, or two selected from R3 through R5 form a 5- to 7-membered ring fused with an aryl

group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O or S atoms;
each of R8, R9 and R10 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl and acetylenyl; and
each of R12 and R15 is independently selected from a group consisting of hydrogen, methyl, ethyl, propyl, methoxy, ethoxy and hydroxy.
【Claim 7】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 6, wherein:
R1 is selected from a group consisting of methyl, ethyl, propyl, butyl, isobutyl, trifluoromethyl, cyclopropyl, ethoxymethyl, methoxymethyl and ethoxyethyl;
each of R3, R4 and R5 is independently selected from a group consisting of hydrogen, fluoro, chloro, nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, methylenedioxy, isopropoxy, hydroxymethyl, hydroxyethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl, acetylenyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, acetyl, methylsulfonyl, methylsulfamoyl, phenylmethyl, phenylethyl and methylthio, or two selected from R3 through R5 form a 5- to 7-membered ring fused with an aryl group together with the carbon atoms to which they are bound and the ring includes 0-2 double bonds and contains 0-2 N, O

or S atoms; and
each of R8, R9 and R10 is independently selected from a group consisting of hydrogen, fluoro, chloro, bromo, iodo, nitro, cyano, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, hydroxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxyvinyl and acetylenyl.
【Claim 8】
The compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to claim 6, wherein the compound is selected from a group consisting of:
2-{[3-(4-methoxyphenyl)-2-methyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a] pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-benzo[1,3]dioxol-5-yl-2-ethoxymethyl-7-(3-methoxyphenyl)-pyrazolo[1,5 -a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[7-(3-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-methyl amino}-ethanol,
2-{[7-(4-fluorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-methyl amino}-ethanol,
2-{[7-(3-chlorophenyl)-2-methyl-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-amino} -ethanol,
2-[2-ethoxymethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[2-ethoxymethyl-7-(4-fluorophenyl)-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-

amino}-ethanol,
2-{3-benzo[1,3]dioxol-5-yl-2-ethoxymethyl-7-(3-trifluoromethylphenyl)-pyrazol o[1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-benzo[1,3]dioxol-5-yl-7-(3-chlorophenyl)-2-ethoxymethyl-pyrazolo[1,5-a] pyrimidin-5-yl]-methylamino}-ethanol,
2-{[2-ethoxymethyl-7-(3-fluorophenyl)-3-p-tolyl-pyrazolo[1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[2-ethoxymethyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimi din-5-yl]-methylamino}-ethanol,
2-{[2-butyl-3-p-tolyl-7-(3-trifluoromethylphenyl)-pyrazolo[1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-2-ethoxymethyl-7-(4-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-2-ethoxymethyl-7-(3-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-2-ethoxymethyl-7-(3-trifluoromethylphenyl)-pyrazolo[1, 5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-2-methoxymethyl-7-(3-trifluoromethylphenyl)-pyrazolo[ 1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-7-(4-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyr imidin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-7-(3-fluorophenyl)-2-methoxymethyl-pyrazolo[1,5-a]pyr imidin-5-yl]-methylamino}-ethanol,
2-{[2-methoxymethyl-3-(4-methoxyphenyl)-7-(3-trifluoromethylphenyl)-pyrazol

o[1,5-a]pyrimidin-5-yl]-methylamino}-ethanol,
2-{[3-(4-chlorophenyl)-2-ethoxymethyl-7-(4-fluorophenyl)-pyrazolo[1,5-a]pyri midin-5-yl]-ethylamino}-ethanol and
2-{[3-(4-chlorophenyl)-2-methoxymethyl-7-(m-tolyl)-pyrazolo[1,5-a]pyrimidin-5 -yl]-methylamino}-ethanol.
【Claim 9】
A pharmaceutical composition comprising the compound, the prodrug thereof, the isomer thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof or the solvate thereof according to any one of claims 1 to 8.
【Claim 10】
The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is for preventing or treating a disease mediated by the cannabinoid receptor-1.
【Claim 11】
The pharmaceutical composition according to claim 10, wherein the disease mediated by the cannabinoid receptor-1 is at least one selected from a group consisting of inflammatory pain, psycopathy, anxiety, depression, attention deficiency, memory or cognitive disorder, neuropathic pain disorder, sexual dysfunction, impulse control disorder, obesity, neurological or obsessive eating

disorder, cancer, morning sickness, nausea, gastric ulcer, diabetes, hypertension, hyperlipidemia, valvular heart disease, myocardial infarction, cardiomegaly and congestive heart failure.
【Claim 12】
The pharmaceutical composition according to claim 10, wherein the disease mediated by the cannabinoid receptor-1 is obesity.
【Claim 13】
The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition prevents or treats obesity through control of appetite, facilitation of energy metabolism or regulation of processes related with fat metabolism.
【Claim 14】
A method for preparing pyrazolo[1,5-a]pyrimidine having an aryl substituent bound at 7-position, comprising reacting aminopyrazole and a diketoester in a pyridine solvent, wherein at least one of the aminopyrazole and the diketoester contains an aryl group.
【Claim 15】
A pyrazolo[1,5-a]pyrimidine compound having an aryl substituent bound at

7-position prepared by the method for preparing pyrazolo[1,5-a]pyrimidine having an aryl substituent bound at 7-position according to claim 14, a prodrug thereof, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof.

Documents

Application Documents

# Name Date
1 Specification.pdf 2013-03-28
2 IB_304.pdf 2013-03-28
3 GPOA.pdf 2013-03-28
4 Form 5.pdf 2013-03-28
5 Form 3.pdf 2013-03-28
6 Drawings(Eng.).pdf 2013-03-28
7 1476-CHENP-2013 FORM-3 23-05-2013.pdf 2013-05-23
8 1476-CHENP-2013 CORRESPONDENCE OTHERS 23-05-2013.pdf 2013-05-23
9 1476-CHENP-2013 FORM-13 05-06-2013.pdf 2013-06-05
10 1476-CHENP-2013 CORRESPONDENCE OTHERS 05-06-2013.pdf 2013-06-05
11 1476-CHENP-2013 AMENDED PAGE OF SPECIFICATION 05-06-2013.pdf 2013-06-05
12 1476-CHENP-2013 AMENDED CLAIMS 05-06-2013.pdf 2013-06-05
13 1476-CHENP-2013 POWER OF ATTORNEY 10-06-2013.pdf 2013-06-10
14 1476-CHENP-2013 FORM-13 10-06-2013.pdf 2013-06-10
15 1476-CHENP-2013 FORM-1 10-06-2013.pdf 2013-06-10
16 1476-CHENP-2013 CORRESPONDENCE OTHERS 10-06-2013.pdf 2013-06-10
17 1476-CHENP-2013-Form 3-280316.pdf 2016-05-19
18 1476-CHENP-2013-Correspondence-280316.pdf 2016-05-19
19 Form 3 [12-09-2016(online)].pdf 2016-09-12
20 Form 3 [10-03-2017(online)].pdf 2017-03-10
21 1476-CHENP-2013.pdf 2017-05-26
22 1476-CHENP-2013-FER.pdf 2018-02-14
23 1476-chenp-2013-Certified Copy of Priority Document (MANDATORY) [05-03-2018(online)].pdf 2018-03-05
24 Correspondence by Agent _English Translation_13-03-2018.pdf 2018-03-13
25 1476-CHENP-2013-OTHERS [06-08-2018(online)].pdf 2018-08-06
26 1476-CHENP-2013-FER_SER_REPLY [06-08-2018(online)].pdf 2018-08-06
27 1476-CHENP-2013-DRAWING [06-08-2018(online)].pdf 2018-08-06
28 1476-CHENP-2013-CORRESPONDENCE [06-08-2018(online)].pdf 2018-08-06
29 1476-CHENP-2013-CLAIMS [06-08-2018(online)].pdf 2018-08-06
30 1476-CHENP-2013-ABSTRACT [06-08-2018(online)].pdf 2018-08-06
31 1476-CHENP-2013-FORM 4(ii) [07-08-2018(online)].pdf 2018-08-07
32 Correspondence by Agent_Verified English Translation_13-08-2018.pdf 2018-08-13
33 1476-CHENP-2013-Information under section 8(2) (MANDATORY) [13-08-2018(online)].pdf 2018-08-13
34 1476-CHENP-2013-HearingNoticeLetter.pdf 2018-11-29
35 1476-CHENP-2013-FORM-26 [13-12-2018(online)].pdf 2018-12-13
36 Correspondence by Agent_Power of Attorney_18-12-2018.pdf 2018-12-18
37 1476-CHENP-2013-FORM 3 [24-01-2019(online)].pdf 2019-01-24
38 1476-CHENP-2013-ExtendedHearingNoticeLetter_04Mar2019.pdf 2019-03-04
39 1476-CHENP-2013-Written submissions and relevant documents (MANDATORY) [08-03-2019(online)].pdf 2019-03-08
40 1476-CHENP-2013-PETITION UNDER RULE 137 [08-03-2019(online)].pdf 2019-03-08
41 Marked up Claims_Granted 317566_02-08-2019.pdf 2019-08-02
42 Drawings_Granted 317566_02-08-2019.pdf 2019-08-02
43 Description_Granted 317566_02-08-2019.pdf 2019-08-02
44 Claims_Granted 317566_02-08-2019.pdf 2019-08-02
45 Abstract_Granted 317566_02-08-2019.pdf 2019-08-02
46 1476-CHENP-2013-PatentCertificate02-08-2019.pdf 2019-08-02
47 1476-CHENP-2013-IntimationOfGrant02-08-2019.pdf 2019-08-02

Search Strategy

1 1476searchstrategy_09-02-2018.pdf

ERegister / Renewals

3rd: 10 Oct 2019

From 31/08/2013 - To 31/08/2014

4th: 10 Oct 2019

From 31/08/2014 - To 31/08/2015

5th: 10 Oct 2019

From 31/08/2015 - To 31/08/2016

6th: 10 Oct 2019

From 31/08/2016 - To 31/08/2017

7th: 10 Oct 2019

From 31/08/2017 - To 31/08/2018

8th: 10 Oct 2019

From 31/08/2018 - To 31/08/2019

9th: 10 Oct 2019

From 31/08/2019 - To 31/08/2020

10th: 25 Jun 2020

From 31/08/2020 - To 31/08/2021